Why Royalty Pharma plc’s (RPRX) Stock Is Down 6.31%
As of Tuesday, September 08, Royalty Pharma plc’s RPRX share price has dipped by 6.31%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Commentary & Analysis
Which Is a Better Investment, AstraZeneca PLC or Royalty Pharma plc Stock?
Learn more about whether AstraZeneca PLC or Royalty Pharma plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
What You Need to Know About Royalty Pharma plc's Q3 Earnings
Royalty Pharma plc's fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (RPRX) missed or beat analyst's expectations.Tudor Pop
Is Royalty Pharma plc (RPRX) Overvalued?
We dive into why Royalty Pharma plc (RPRX) could be considered overvalued on 2026-07-20, based on AAII’s Value Score and Grade.Tudor Pop
What You Need to Know About Royalty Pharma plc's Q2 Earnings
Royalty Pharma plc's fiscal Q2 earnings report was released on Wednesday, May 06. Let's dive in to see if (RPRX) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $26,979.4 | $646.4 | 89% |
|
| Shares Out (Mil) | 556.9 | 43.4 | 89% |
|
| Institutional Ownership | 93.3% | 83.9% | 63% |
|
| Float (Mil) | 415.5 | 45.7 | 83% |
|
| Beta | 0.43 | 0.73 | 24% |
|
| Avg Daily Volume (000s) | 3,408 | 299 | 90% |
|
| Price Change (52-week) |
69.3% | 67.8% | 87% |
|
| Growth | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.3% | 6.7% | 24% |
|
| Net Income (5yr) | (4.6%) | (1.4%) | 34% |
|
| EPS (5yr) | 6.2% | 15.1% | 40 |
|
| Dividends (5yr) | 24.0% | 0.0% | 77% |
|
| Cash Flow (5yr) | (18.7%) | (15.0%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | $1.181 | $5.343 | $5.734 | |
| Month Ago EPS | $1.161 | $5.312 | $5.682 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $1.130 | $5.117 | $5.614 | |
| Year/Year Chg | 2,853% | 200.0% | 265.4% | |
| Financials | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,536 | $304 | 64% |
|
| Net Income (TTM) (Mil) | $812 | ($11) | 84% |
|
| EPS (TTM) | $1.864 | ($0.700) | 70% |
|
| Operating Cash Flow (TTM) (Mil) | $2,977 | ($6) | 91% |
|
| Net Cash Flow (TTM) (Mil) | $180 | $6 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $8,582 | $6 | 90% |
|
| Enterprise Value (Q1) (Mil) | $38,378 | $524 | 90% |
|
| Valuation | RPRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.95 | 2.72 | 73% |
|
| P/E | 32.5 | 16.9 | 73% |
|
| Dividend Yield | 1.6% | 0.0% | 73% |
|
| PEG (5yr hist) | 5.2 | 1.0 | 88% |
|
| Ratios | RPRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 95.8% | 68.1% | 95% |
|
| Net Margin | 32.0% | (2.3%) | 90% |
|
| ROA | 4.3% | (24.1%) | 68% |
|
| ROE | 12.3% | (21.4%) | 64% |
|
| Liabilities to Assets | 50.6% | 32.6% | 43% |
|
| F-Score | 5 | 3 | 50% |
|
Royalty Pharma plc did not pass any screens on 9/9/2026.
